» Articles » PMID: 17466295

Role for Btg1 and Btg2 in Growth Arrest of WEHI-231 Cells Through Arginine Methylation Following Membrane Immunoglobulin Engagement

Overview
Journal Exp Cell Res
Specialty Cell Biology
Date 2007 May 1
PMID 17466295
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Engagement of membrane Ig (mIg) on WEHI-231 murine B lymphoma cells, a cell line model representative of primary immature B cells, results in growth arrest and subsequent apoptosis. Of the several dozen genes upregulated greater than two-fold by anti-IgM treatment through DNA microarray analysis, we focused on B cell translocation gene 1 (Btg1) and Btg2, member of Btg/Tob family of proteins. WEHI-231 cells were infected with the Btg1/EGFP or Btg2/EGFP retroviral vectors, and those expressing either Btg1 or Btg2 accumulated in G1 phase at significantly higher proportions than that seen for cells expressing control vector. Btg1 or Btg2 bound to protein arginine methyltransferase (PRMT) 1 via the box C region, an interaction required for anti-IgM-induced growth inhibition. The arginine methyltransferase inhibitor AdOx partially abrogated growth inhibition induced by Btg1, Btg2, or anti-IgM. The Btg1- or Btg2-induced growth inhibition was also abrogated in PRMT1-deficient cells via introduction of small interference RNA. In addition, we observed anti-IgM-induced arginine methylation of two proteins, a 28-kDa and a 36-kDa protein. Methylation, detected by a monoclonal antibody specific for asymmetric, but not symmetric methyl residues, was observed as early as 1 h-2 h after stimulation and was sustained for up to 24 h. The anti-IgM-induced p36 arginine methylation was abrogated in the PRMT1-deficient cells, suggesting that PRMT1 induces p36 methylation. Together, these results suggest that anti-IgM-induced growth inhibition is mediated via upregulation of Btg1 and Btg2, resulting in the activation of arginine methyltransferase activity and culminating in growth inhibition of WEHI-231 cells.

Citing Articles

mutation yields supercompetitive B cells primed for malignant transformation.

Mlynarczyk C, Teater M, Pae J, Chin C, Wang L, Arulraj T Science. 2023; 379(6629):eabj7412.

PMID: 36656933 PMC: 10515739. DOI: 10.1126/science.abj7412.


Emerging role of anti-proliferative protein BTG1 and BTG2.

Kim S, Jung I, Hwang S BMB Rep. 2022; 55(8):380-388.

PMID: 35880434 PMC: 9442347.


Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants.

Kots E, Mlynarczyk C, Melnick A, Khelashvili G Biophys J. 2022; 121(19):3753-3764.

PMID: 35459639 PMC: 9617077. DOI: 10.1016/j.bpj.2022.04.023.


A conserved motif in human BTG1 and BTG2 proteins mediates interaction with the poly(A) binding protein PABPC1 to stimulate mRNA deadenylation.

Amine H, Ripin N, Sharma S, Stoecklin G, Allain F, Seraphin B RNA Biol. 2021; 18(12):2450-2465.

PMID: 34060423 PMC: 8632095. DOI: 10.1080/15476286.2021.1925476.


Flip the switch: BTG2-PRMT1 protein complexes antagonize pre-B-cell proliferation to promote B-cell development.

Wu G, Bassing C Cell Mol Immunol. 2018; 15(9):808-811.

PMID: 29429994 PMC: 6203761. DOI: 10.1038/cmi.2017.156.